Search - tctmd.com

Displaying 1 - 20 of 82

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

Todd Neale

September 13, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Conference News ADA 2023

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Michael O'Riordan

June 28, 2023

News Daily News

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

Yael L. Maxwell

February 21, 2023

News Daily News

CT Angiography Is Increasing in England, but Downstream Tests Are Not

Michael O'Riordan

January 12, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

News

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

Todd Neale

June 17, 2022

News Daily News

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

Michael O'Riordan

January 25, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Erectile Dysfunction Drugs Show Cardioprotective Effects in Low-risk Men

CT Angiography Is Increasing in England, but Downstream Tests Are Not

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

Optimal Medical Therapy for Stable Angina: Which Drugs? How Long?

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content